培美曲塞治疗老年中晚期非小细胞肺癌的临床效果

目的：观察培美曲赛单药治疗老年中晚期非小细胞肺癌的疗效和不良反应。方法：总结分析于本院诊治2008—2009年26例老年（70～81岁）ⅢA-Ⅳ期非小细胞肺癌患者接受培美曲赛单药化疗2周期后行临床疗效和不良反应。结果：完全缓解（CR）0例,部分缓解（PR）6例,总有效率为23．08％,疾病稳定（SD）11例,疾病进展（PD）9例。全组毒性不良反应较轻,主要为骨髓抑制,可耐受。结论：培关曲赛治疗老年非小细胞肺癌疗效较好,不良反应轻,可明显改善老年患者生存质量。

Clinical observation of pemetrexed in treating elder advanced non-small cell lung cancer

Objective：To evaluate the clinical efficacy and adverse effect of pemetrexed monotherapy in elderly patients with intermediate or late-stage non-small cell lung cancer（ NSCLC ）. Method：Twenty-six elderly patients（aged 70-81 years） with advanced non-small cell lung cancer（ stages Ⅲa to Ⅳ） received pemetrexed monotherapy. The patients were evaluated for clinical efficacy and adverse effects after 2 cycles. Results： Complete remission（CR） was observed in none and PR in 6 of the cases. The total response rate was 23.08% （6/ 26）. There were 11 patients with stable disease and 9 with progressive disease. The adverse effects were generally mild and mainly included bone marrow suppression which was tolerable. Conclusion：The regimen of pemetrexed is effective, safe and well-tolerated, and provides significant improvement in quality of life among elderly patients with advanced NSCLC.